Literature DB >> 29425377

Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study.

Kathryn L Taylor1, George Luta2, Richard M Hoffman3,4, Kimberly M Davis1, Tania Lobo1, Yingjun Zhou1, Amethyst Leimpeter5, Jun Shan5, Roxanne E Jensen1, David S Aaronson6, Stephen K Van Den Eeden5.   

Abstract

As many as 40% of men diagnosed with prostate cancer have low-risk disease, which results in the need to decide whether to undergo active treatment (AT) or active surveillance (AS). The treatment decision can have a significant effect on general and prostate-specific quality of life (QOL). The purpose of this study was to assess the QOL among men with low-risk prostate cancer during the first year following diagnosis. In a prospective cohort study, we conducted pretreatment telephone interviews (N = 1,139; 69.3% response rate) with low-risk PCa patients (PSA ≤ 10, Gleason ≤ 6) and a follow-up assessment 6-10 months postdiagnosis (N = 1057; 93%). We assessed general depression, anxiety, and physical functioning, prostate-specific anxiety, and prostate-specific QOL at both interviews. Clinical variables were obtained from the medical record. Men were 61.7 (SD = 7.2) years old, 82% white, 39% had undergone AT (surgery or radiation), and 61.0% had begun AS. Linear regression analyses revealed that at follow-up, the AS group reported significantly better sexual, bowel, urinary, and general physical function (compared to AT), and no difference in depression. However, the AS group did report greater general anxiety and prostate-specific anxiety at follow-up, compared to AT. Among men with low-risk PCa, adjusting for pretreatment functioning, the AS group reported better prostate-related QOL, but were worse off on general and prostate-specific anxiety compared to men on AT. These results suggest that, within the first year postdiagnosis, men who did not undergo AT may require additional support in order to remain comfortable with this decision and to continue with AS when it is clinically indicated.

Entities:  

Mesh:

Year:  2018        PMID: 29425377      PMCID: PMC6256951          DOI: 10.1093/tbm/ibx005

Source DB:  PubMed          Journal:  Transl Behav Med        ISSN: 1613-9860            Impact factor:   3.046


  47 in total

1.  Sexual function with localized prostate cancer: active surveillance vs radical therapy.

Authors:  Roderick C N van den Bergh; Ida J Korfage; Monique J Roobol; Chris H Bangma; Harry J de Koning; Ewout W Steyerberg; Marie-Louise Essink-Bot
Journal:  BJU Int       Date:  2012-01-19       Impact factor: 5.588

Review 2.  How does active surveillance for prostate cancer affect quality of life? A systematic review.

Authors:  Lara Bellardita; Riccardo Valdagni; Roderick van den Bergh; Hans Randsdorp; Claudia Repetto; Lionne D F Venderbos; J Athene Lane; Ida J Korfage
Journal:  Eur Urol       Date:  2014-10-31       Impact factor: 20.096

3.  Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors.

Authors:  Ravishankar Jayadevappa; Stanley Bruce Malkowicz; Marsha Wittink; Alan J Wein; Sumedha Chhatre
Journal:  Health Serv Res       Date:  2012-03-14       Impact factor: 3.402

4.  Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment.

Authors:  David Cella; Seung Choi; Sofia Garcia; Karon F Cook; Sarah Rosenbloom; Jin-Shei Lai; Donna Surges Tatum; Richard Gershon
Journal:  Qual Life Res       Date:  2014-06-18       Impact factor: 4.147

5.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

6.  Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.

Authors:  Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

7.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

Authors:  David M Latini; Stacey L Hart; Sara J Knight; Janet E Cowan; Phillip L Ross; Janeen Duchane; Peter R Carroll
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

8.  Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study.

Authors:  Richard M Hoffman; William C Hunt; Frank D Gilliland; Robert A Stephenson; Arnold L Potosky
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

9.  Quality of life three years after diagnosis of localised prostate cancer: population based cohort study.

Authors:  David P Smith; Madeleine T King; Sam Egger; Martin P Berry; Phillip D Stricker; Paul Cozzi; Jeanette Ward; Dianne L O'Connell; Bruce K Armstrong
Journal:  BMJ       Date:  2009-11-27

10.  The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients.

Authors:  Chantal Quinten; Corneel Coens; Irina Ghislain; Efstathios Zikos; Mirjam A G Sprangers; Jolie Ringash; Francesca Martinelli; Divine E Ediebah; John Maringwa; Bryce B Reeve; Eva Greimel; Madeleine T King; Kristin Bjordal; Hans-Henning Flechtner; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Hans Wildiers; Galina Velikova; Andrew Bottomley
Journal:  Eur J Cancer       Date:  2015-11-19       Impact factor: 9.162

View more
  3 in total

Review 1.  Patient perception of receiving a thyroid cancer diagnosis.

Authors:  Catherine B Jensen; Susan C Pitt
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-10-01       Impact factor: 3.626

2.  Cognitive function, depression, and anxiety in patients undergoing radical prostatectomy with and without adjuvant treatment.

Authors:  Piotr Jarzemski; Bartosz Brzoszczyk; Alicja Popiołek; Agnieszka Stachowicz-Karpińska; Szymon Gołota; Maciej Bieliński; Alina Borkowska
Journal:  Neuropsychiatr Dis Treat       Date:  2019-04-05       Impact factor: 2.570

3.  Psychological predictors of delayed active treatment following active surveillance for low-risk prostate cancer: The Patient REported outcomes for Prostate cARE prospective cohort study.

Authors:  Kathryn L Taylor; George Luta; Vasiliki Zotou; Tania Lobo; Richard M Hoffman; Kimberly M Davis; Arnold L Potosky; Tengfei Li; David Aaronson; Stephen K Van Den Eeden
Journal:  BJUI Compass       Date:  2021-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.